ARB102A / Arbele - LARVOL DELTA

Collaboration with Chime Biologics: Accelerated CMC Process Development of novel ADC and TCE (PRNewswire) - "Arbele has entered a strategic alliance with Chime Biologics to accelerate chemistry, manufacturing and control (CMC) process development of the novel designs of ADCs and TCEs....The collaboration will ensure Arbele continues to have at least 1-2 new molecular entities (NMEs) successfully filing for investigational new drug (IND) application and entering clinical studies in the next 5 years without any technical and supply-chain interruptions. The first deliverable will be anti-CDH17 ADC (ARB102A), for IND submission in early 2025."

Commercial • IND • Oncology